jpans

v2n2-jpans 1351844258

Development and Shelf Stability of Natural Fibre Rich Retort Pouch Ready to Eat Products
Pages 114-123
C.R. Vasudish, S. Nataraj and K.S. Premavalli
DOI:
http://dx.doi.org/10.6000/1927-5951.2014.04.02.7
Published: 30 April 2014


Abstract: The new frontier in the food research is the role of non nutritive components in human health. In the recent past, the importance of dietary fibre in the diet has been increased as a functional ingredient which has opened up a potential market for fibre rich products. The by products available during processing of plant foods are considered as promising source of functional fibres. The aim of the present study was to develop fibre rich products using the natural fibre such as ashgourd (Benincasa hispida) fibre, with high soluble fibre fraction. Ready-to-eat fibre rich Bisi bele bath and vegetable pulav were developed with the optimization of fibre using statistical design software. Fibre, fat and spice mixtures were independent variables with the other components as fixed factors. Since the product acceptance is more dependent on volatile compound form intern the flavour, as well as depends on the test, appearance, colour, texture which are the sensory attributes, total volatiles and sensory attributes were selected as responses. While in the fibre rich vegetable pulav water, fibre and spice mixtures were the independent variables. Both the products were showing good acceptability i.e. in the case of bisi bele bhath 7.1 and in the case of vegetable pulav 6.5 on a 9 point hedonic scale after 6 months of storage at room temperature. The dietary fibre profile of bisi bele bhath was 1.1% soluble fibre and 4.4% insoluble fibre while vegetable pulav had 6.2% insoluble and 1.54% soluble fibre fraction. The products were safe and had an established shelf life of 6 months.

Keywords: Natural fibre, RSM, Retort processing, dietary fibre, sensory analysis.
Download Full Article

v2n2-jpans 1351844258

Investigation for the Effects of Omega 3 Fatty Acid and Glutamine-L-Alanine on Morbidity and Mortality in the Critically ILL Patients after Major Abdominal Surgery
Pages 124-130
Kaya Bulut Gulsen, Ozgultekin Asu, Turan Guldem, Isıtmangil Gulbu, Terzioglu Ufuk, Kurt Nurettin and Ekinci Osman
DOI:
http://dx.doi.org/10.6000/1927-5951.2014.04.02.8
Published: 30 April 2014


Abstract: Background & Objectives: This study investigated the effects for the addition of omega 3 fatty acids and glutamine-L-alanine to the standard enteral and/or parenteral nutrition regimen on infection and mortality in the critically ill patients after major abdominal surgery.

Methods: This is a prospective, randomized, single center study. A total of 43 patients (age range: 18-85 years), who were in the critical care unit after major abdominal surgery, were included. Patients were divided into two groups according to simple randomized selection [Control group, n=20; Study Group, n=23 (omega3 fatty acids and glutamine-L-alanine)] and were monitored for 21 days. Patients were examined for the assessment of APACHE II Score and existence of ALI (acute lung injury)/ARDS (acute respiratory distress syndrome) requiring mechanical ventilation. In addition to standard enteral or parenteral nutrition, patients in the study group were given parenteral pharmaconutrition products for 10 days postoperatively. Groups were compared for the duration of mechanical ventilation, duration of stay in the intensive care unit and hospitalization, and mortality. Laboratory parameters including CRP, TNFα, IL6, IL8, nitrogen balance, albumin, and total lymphocyte count were recorded.

Results:Although the mean APACHE score was higher in study group in which patients received omega-3 fatty acids and glutamine-L-alanine support, the clinical infection rate seemed to decrease insignificantly.

Conclusions: A clinically decreased rate of infection was observed in patients with a high APACHE II score, or who received omega-3 fatty acids, glutamine-L-alanine, are required to be administered more selectively and in larger patient groups in different doses and in combination protocols in accordance with the current pharmaconutritional support and in different timing combinations, including preoperative period.

Keywords: Omega-3, glutamine- L-alanine, enteral nutrition, parenteral nutrition, ICU.
Download Full Article

v2n2-jpans 1351844258

Response to Ustekinumab in a Patient with Severe Psoriasis when Adalimumab Dose Escalation Fails
Pages 131-134
Joaquín Borrás-Blasco, Luisa Obon, Isabel Hernández, Dolores-Elvira Casterá, Alejandro Gonzalez\, F. Javier Abadand J. Dolores Rosique-Robles
DOI:
http://dx.doi.org/10.6000/1927-5951.2014.04.02.9
Published: 30 April 2014


Abstract: Objectives: To report a case of response to ustekinumab in a patient with severe psoriasis when adalimumab dose escalation fail.

Case Description: A 35-year-old Caucasian male was diagnosed as having psoriasis. He was started on methotrexate followed cyclosporine. Despite these treatments, the patient experienced an abrupt deterioration of his psoriasis [PASI 35]. The patient started treatment with adalimumab: initial dose of 80mg followed by 40mg in week 2. At week 3 he continued on adalimumab 40mg/two weeks with significant reduction of psoriasis. After 8 months of adalimumab therapy, he referred that adalimumab was effective only during the first week of treatment. The patient gave his written informed consent for adalimumab dose intensification. He started adalimumab 40mg/week, with an improvement of psoriasis. After 7 months of adalimumab dose intensification, the psoriasis worsened [PASI score =25 and CDLQI score 20]. We discontinued adalimumab and started therapy with ustekinumab, 45mg subcutaneously, was administered at weeks 0, 4 and every 12 weeks. The clinical response was impressive; at week 12 a PASI 90 response was achieved while the CDLQI score fell to the scale of 7. Efficacy was maintained after a 12 months of ustekinumab therapy.

Conclusions: This case report provides valuable insight into the efficacy and tolerability of ustekinumab in a patient with severe psoriasis when adalimumab dose escalation fails. To our knowledge this is the first case published to date that describes the clinical efficacy of ustekinumab when adalimumab intensification dose escalation fails.

Keywords: Ustekinumab, adalimumab, psoriasis, dose escalation.
Download Full Article

v2n2-jpans 1351844258

Synthesis, Spectral Characterization, Docking Studies and QSAR Screening of 4-amino-benzenesulfonamides/N-acetyl 4-amino-benzenesulfonamide Derivatives as Antimicrobial Agents 
Pages 135-153
Ajeet, Laxmi Tripathi and Arvind Kumar
DOI:
http://dx.doi.org/10.6000/1927-5951.2014.04.02.10
Published: 30 April 2014


Abstract: A series of substituted 4-amino-benzenesulfonamides / N-acetyl-4-amino-benzenesulfonamide were designed & synthesized keeping in view the structural requirements of pharmacophore and were evaluated for in-silico antimicrobial activity. For establishing the structure, spectral characterization like FT-IR, 1H NMR, GC-MS and elemental analysis (CHNS) has been performed. The antimicrobial activity of the titled compounds was assessed using in-silico studies (QSAR screening and Docking). It was carried out for the prediction of pharmacokinetic properties and to study the binding properties of drugs with molecular targets. Titled compounds exhibited good binding properties with molecular target. It could be concluded that molecular target responsible for the antimicrobial activity of substituted 4-amino-benzenesulfonamides / N-acetyl-4-amino-benzenesulfonamides may be pseudomonas aeruginosa exotoxin A.

Keywords: Sulfonamide, in-silico studies, statistics, quantitative structure activity relationship.

Download Full Article